Bispecific antibodies of FAP and IL-2 receptor (RO6874281) or 1BBL (RG7826) are being tested in combination with ICBs on clinical trials and have shown to be safe, and preclinical models encourage the advancement due to promising results such as tumor regression, accumulation of CD8+ T and NK cells. This evidence concerns the gene CD8A and neoplasm.